Profile Picture
Google ScholarScopusORCIDPublons
Organizational Units
Organizational Unit
Job Title
First Name
Last Name
Email Address
Birth Date

Search Results

Now showing 1 - 10 of 26
  • PublicationMetadata only
    Minimal Değişim Hastalığı
    (Akademisyen Yayınevi Kitabevi, 2021-01-01) Gürsu M.; GÜRSU, MELTEM
  • PublicationMetadata only
    Hemodiyaliz Cihazı
    (Güneş Kitabevi, 2020-01-01) Gürsu M.; GÜRSU, MELTEM
  • PublicationOpen Access
    Acute kidney injury in Turkey: epidemiological characteristics, etiology, clinical course, and prognosis
    (2022-10-01T00:00:00Z) GÜRSU, Meltem; Yegenaga, Itir; TUĞLULAR, ZÜBEYDE SERHAN; DURSUN, BELDA; GÖKÇAY BEK, SİBEL; Bardak, Simge; ONAN, ENGİN; Demir, Serap; DERİCİ, ÜLVER; DOĞUKAN, AYHAN; Sevinc, Mustafa; KOÇYİĞİT, İSMAİL; Altun, Eda; Haras, Ali Burak; ALTIPARMAK, Mehmet Rıza; TONBUL, HALİL ZEKİ; GÜRSU, MELTEM
    Background: This study aimed to evaluate the etiologies, comorbidities, and outcomes of acute kidney injury (AKI) in Turkey and determine any potential differences among different geographical parts of the country. Methods: This prospective observational study was conducted by the Acute Kidney Injury Working Group of the Turkish Society of Nephrology. Demographical and clinical data of patients with AKI at the time of diagnosis and at the 1st week and 1st, 3rd, and 6th months of diagnosis were evaluated to determine patient and renal survival and factors associated with patient prognosis. Results: A total of 776 patients were included (54.7% male, median age: 67 years). Prerenal etiologies, including dehydration, heart failure, and sepsis, were more frequent than other etiologies. 58.9% of the patients had at least one renal etiology, with nephrotoxic agent exposure as the most common etiology. The etiologic factors were mostly similar throughout the country. 33.6% of the patients needed kidney replacement therapy. At the 6th month of diagnosis, 29.5% of the patients had complete recovery; 34.1% had partial recovery; 9.5% developed end-stage kidney disease; and 24.1% died. The mortality rate was higher in the patients from the Eastern Anatolian region; those admitted to the intensive care unit; those with prerenal, renal, and postrenal etiologies together, stage 3 AKI, sepsis, cirrhosis, heart failure, and malignancy; those who need kidney replacement therapy; and those without chronic kidney disease than in the other patients. Conclusion: Physicians managing patients with AKI should be alert against dehydration, heart failure, sepsis, and nephrotoxic agent exposure. Understanding the characteristics and outcomes of patients with AKI in their countries would help prevent AKI and improve treatment strategies.
  • PublicationMetadata only
    Fizyolojik prensipler ve üre kinetik modeli
    (Güneş Kitabevi, 2020-01-01) Gürsu M.; GÜRSU, MELTEM
  • PublicationOpen Access
    COVİD-19 infection in a membranous nephropathy patient treated with rituximab.
    (2020-09-04T00:00:00Z) Elcioglu, Omer Celal; Artan, Ayse Serra; Mirioglu, Safak; Gursu, Meltem; Durdu, Bulent; Koc, Meliha Meric; Okyaltirik, Fatmanur; Gultekin, Mehmet Ali; Kazancioglu, Rümeyza; ELÇİOĞLU, ÖMER CELAL; MİRİOĞLU, ŞAFAK; GÜRSU, MELTEM; DURDU, BÜLENT; MERİÇ KOÇ, MELİHA; OKYALTIRIK, FATMANUR; GÜLTEKİN, MEHMET ALİ; KAZANCIOĞLU, RÜMEYZA
    While COVID-19 pandemic continues to afect our country and most countries in the world, we have to make some changes both in our social life and our approach to healthcare. We have to struggle with the pandemic on one hand and also try to follow up and treat our patients with chronic diseases in the most appropriate way. In this period, one of our group of patients who are challenging us for follow-up and treatment are those who should start or continue to use immunosuppressive therapy. In order to contribute to the accumulation of knowledge in this area, we wanted to report a patient who was followed up with the diagnosis of COVID-19 and had been administered rituximab very recently due to a nephrotic syndrome caused by membranous nephropathy.
  • PublicationMetadata only
    Nadir Bir Kateter İlişkili Enfeksiyon Etkeni; Achromobacter Denitrificans
    (2022-11-09) Çıngar Alpay K.; Gürsu M.; Elçioğlu Ö. C.; Mirioğlu Ş.; Kazancıoğlu R.; ÇINGAR, KÜBRA; GÜRSU, MELTEM; ELÇİOĞLU, ÖMER CELAL; MİRİOĞLU, ŞAFAK; KAZANCIOĞLU, RÜMEYZA
  • PublicationMetadata only
    Covid-19 Pandemisinin Peritonit Hızı Üzerine Etkisi
    (2022-11-09) Gürsu M.; Mirioğlu Ş.; Köse E.; Yücel L.; Sayan C.; Elçioğlu Ö. C.; Kazancıoğlu R.; GÜRSU, MELTEM; MİRİOĞLU, ŞAFAK; ELÇİOĞLU, ÖMER CELAL; KAZANCIOĞLU, RÜMEYZA
  • PublicationMetadata only
    (2022-11-01) GÜRSU M.; ÖZTÜRK S.; ARICI M.; Sahin I.; Goekcay Bek S.; Yilmaz M.; Koyuncu S.; Karahisar Sirali S.; Ural Z.; Dursun B.; et al.; GÜRSU, MELTEM
    Background: We aimed to study the characteristics of peritoneal dialysis (PD) patients with Coronavirus disease-19 (COVID-19), determine the short-term mortality and other medical complications, and delineate the factors associated with COVID-19 outcome.Methods: In this multicenter national study, we included PD patients with confirmed COVID-19 from 27 centers. The baseline demographic, clinical, laboratory, and radiological data and outcomes at the end of the first month were recorded.Results: We enrolled 142 COVID-19 patients (median age:52 years). 58.2% of patients had mild disease at diagnosis. Lung involvement was detected in 60.8% of patients. 83 (58.4%) patients were hospitalized, 31 (21.8%) patients were admitted to intensive care unit and 24 needed mechanical ventilation. 15 (10.5%) patients were switched to hemodialysis and hemodiafiltration was performed for four (2.8%) patients. Persisting pulmonary symptoms (n=27), lower respiratory system infection (n=12), rehospitalization for any reason (n=24), malnutrition (n=6), hypervolemia (n=13), peritonitis (n=7), ultrafiltration failure (n=7) and in PD modality change (n=8) were reported in survivors. 26 patients (18.31%) died in the first month of diagnosis. The non-survivor group was older, comorbidities were more prevalent. Fever, dyspnea, cough, serious-vital disease at presentation, bilateral pulmonary involvement, and pleural effusion were more frequent among non-survivors. Age (OR:1.102; 95%CI: 1.032-1.117; p: 0.004), moderate-severe clinical disease at presentation (OR:26.825; 95%CI: 4.578-157.172; p<0.001) and baseline CRP (OR:1.008; 95%CI; 1.000-1.016; p:0.040) were associated with first-month mortality in multivariate analysis.Conclusions: Early mortality rate and medical complications are quite high in PD patients with COVID-19. Age, clinical severity of COVID-19, and baseline CRP level are the independent parameters associated with mortality.
  • PublicationMetadata only
    The Effect of Autosomal Dominant Polycystic Kidney Disease on Spirometric Parameters
    (2020-10-01T00:00:00Z) Ozler, Tuba Elif; Karandere, Faruk; Cebeci, Egemen; GÜRSU, Meltem; Doner, Baris; Sumnu, Abdullah; Sari, Mustafa; Cakmak, Gulfidan; Karaali, Zeynep; Ozturk, Savas; GÜRSU, MELTEM
    Aim: There is no enough data on pulmonary involvement in autosomal dominant polycystic kidney disease (ADPKD). The aim of this study is to examine pulmonary function test in patients with ADPKD with varying stages of renal function and to compare them with those in healthy controls.
  • PublicationMetadata only
    (İstanbul Kitabevi, 2022-01-01) Gürsu M.; GÜRSU, MELTEM